Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.
Adjuvant
Ipilimumab
Melanoma
Metastatic
Neoadjuvant
Nivolumab
PD-1
Pembrolizumab
Relatlimab
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
29
09
2023
accepted:
25
10
2023
medline:
22
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
aheadofprint
Résumé
In the last decade, immunotherapy has become the cornerstone in the management of patients with melanoma, the foremost cause of skin-cancer-related death in the USA. The emergence of immune checkpoint blockade as a crucial element in current immunotherapy and combination strategies has significantly transformed the treatments of resectable and advanced (unresectable or metastatic) melanoma. This paper reviews the landmark clinical trials that formed the basis of management of melanoma in the perioperative and metastatic setting. Furthermore, we discuss the rationale for the applications of PD-1 blockade and its combination with anti-CTLA-4 and anti-LAG-3. The review also explores new experimental combinations of PD-1 blockade with other immunomodulatory agents, including targeted therapies, anti-TIGIT antibodies, TLR-9 agonists, antiangiogenic agents, and mRNA vaccines.
Identifiants
pubmed: 37989956
doi: 10.1245/s10434-023-14587-w
pii: 10.1245/s10434-023-14587-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : T32 CA233414
Pays : United States
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
doi: 10.3322/caac.21763
Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. 1993;3(4):291–9.
Legha S, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann Oncol. 1996;7(8):827–35.
doi: 10.1093/oxfordjournals.annonc.a010762
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
doi: 10.1038/nrc3239
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–99.
doi: 10.1038/nri3862
Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–9.
doi: 10.1038/ni.2035
Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–62.
doi: 10.1016/j.ccell.2018.03.012
Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251–9.
doi: 10.1038/s41591-019-0522-3
Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nat Rev Dis Primers. 2015;1:15003. https://doi.org/10.1038/nrdp.2015.3 .
doi: 10.1038/nrdp.2015.3
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. NEJM. 2012;366(26):2443–54.
doi: 10.1056/NEJMoa1200690
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. NEJM. 2012;366(26):2455–65.
doi: 10.1056/NEJMoa1200694
Robert C, Long GV, Brady B, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38(33):3937–46. https://doi.org/10.1200/JCO.20.00995 .
doi: 10.1200/JCO.20.00995
Larkin J, Minor D, D’Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383–90. https://doi.org/10.1200/JCO.2016.71.8023 .
doi: 10.1200/JCO.2016.71.8023
Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903.
doi: 10.1016/S1470-2045(17)30380-7
Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. https://doi.org/10.1016/S1470-2045(19)30388-2 .
doi: 10.1016/S1470-2045(19)30388-2
Sznol M. Blockade of the B7–H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014;20(4):290–5.
doi: 10.1097/PPO.0000000000000056
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. https://doi.org/10.1056/NEJMoa1302369 .
doi: 10.1056/NEJMoa1302369
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. Wolters Kluwer Health; 2021.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836 .
doi: 10.1056/NEJMoa1910836
Carlino MS, Menzies AM, Atkinson V, et al. Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma: KEYNOTE-029 part 1B. Clin Cancer Res. 2020;26(19):5086–91. https://doi.org/10.1158/1078-0432.CCR-20-0177 .
doi: 10.1158/1078-0432.CCR-20-0177
Lebbe C, Meyer N, Mortier L, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J Clin Oncol. 2019;37(11):867–75. https://doi.org/10.1200/JCO.18.01998 .
doi: 10.1200/JCO.18.01998
Lebbe C, Meyer N, Mortier L, et al. Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511. Wolters Kluwer Health; 2021.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740–6.
doi: 10.1002/cncr.26111
Eggermont AM, Chiarion-Sileni V, Grob J-J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.
doi: 10.1016/S1470-2045(15)70122-1
Tarhini AA, Lee SJ, Hodi FS, et al. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609. J Clin Oncol. 2020;38(6):567.
doi: 10.1200/JCO.19.01381
Ascierto PA, Del Vecchio M, Mandala M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465–77. https://doi.org/10.1016/S1470-2045(20)30494-0 .
doi: 10.1016/S1470-2045(20)30494-0
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801. https://doi.org/10.1056/NEJMoa1802357 .
doi: 10.1056/NEJMoa1802357
Bottomley A, Coens C, Mierzynska J, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):655–64. https://doi.org/10.1016/S1470-2045(21)00081-4 .
doi: 10.1016/S1470-2045(21)00081-4
Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. NEJM. 2017;377(19):1813–23.
doi: 10.1056/NEJMoa1708539
Moncrieff MD, Lo SN, Scolyer RA, et al. Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: implications for the management of American Joint Committee on Cancer IIIA Disease. J Clin Oncol. 2022;40(34):3940–51.
doi: 10.1200/JCO.21.02488
Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517–27. https://doi.org/10.1200/JCO.22.00533 .
doi: 10.1200/JCO.22.00533
Su D, Kluger H, Weiss SA. CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma? Ann Transl Med. 2023;11(10):370. https://doi.org/10.21037/atm-23-754 .
doi: 10.21037/atm-23-754
Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23(11):1378–88. https://doi.org/10.1016/S1470-2045(22)00559-9 .
doi: 10.1016/S1470-2045(22)00559-9
Yoon C, Ross M, Gastman B, et al. Adjuvant pembrolizumab in Stage II melanoma: outcomes by tumor location in the Phase 3 KEYNOTE-716 Study. 2023;
Long GV, Del Vecchio, M., Weber J. Adjuvant therapy with nivolumab versus placebo in pateints with resected stage IIB/IIC melanoma (CheckMate 76K). 2022.
Adjuvant nivolumab treatment in stage II (IIA, IIB, IIC) high-risk melanoma (NivoMela).
Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION). ClinicalTrials.gov Identifier: NCT04901988.
Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. J Clin Oncol. 2018;36(35):3441.
doi: 10.1200/JCO.18.01219
Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20(7):e378–89. https://doi.org/10.1016/S1470-2045(19)30332-8 .
doi: 10.1016/S1470-2045(19)30332-8
Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–61. https://doi.org/10.1038/s41591-019-0357-y .
doi: 10.1038/s41591-019-0357-y
Najjar YG, McCurry D, Lin H, et al. Neoadjuvant pembrolizumab and high-dose ifnalpha-2b in resectable regionally advanced melanoma. Clin Cancer Res. 2021;27(15):4195–204. https://doi.org/10.1158/1078-0432.CCR-20-4301 .
doi: 10.1158/1078-0432.CCR-20-4301
Patel SP, Othus M, Chen Y, et al. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. NEJM. 2023;388(9):813–23.
doi: 10.1056/NEJMoa2211437
Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–54. https://doi.org/10.1038/s41591-018-0197-1 .
doi: 10.1038/s41591-018-0197-1
Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655–61. https://doi.org/10.1038/s41591-018-0198-0 .
doi: 10.1038/s41591-018-0198-0
Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023; https://doi.org/10.1016/j.annonc.2023.01.004
Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178–88. https://doi.org/10.1038/s41591-022-01851-x .
doi: 10.1038/s41591-022-01851-x
Lucas MW, Lijnsvelt J, Pulleman S, et al. The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. American Society of Clinical Oncology; 2022.
Lythgoe MP, Liu DSK, Annels NE, Krell J, Frampton AE. Gene of the month: lymphocyte-activation gene 3 (LAG-3). J Clin Pathol. 2021;74(9):543–7.
doi: 10.1136/jclinpath-2021-207517
Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape LAG-3 and PD-1 synergistically prevent antitumor immunity. Cancer Res. 2012;72(4):917–27.
doi: 10.1158/0008-5472.CAN-11-1620
Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. https://doi.org/10.1056/NEJMoa2109970 .
doi: 10.1056/NEJMoa2109970
Tawbi HA, Hodi FS, Lipson EJ, et al. Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. American Society of Clinical Oncology; 2023.
Baramidze A, Gogishvili M, Makharadze T, et al. A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma. American Society of Clinical Oncology; 2023.
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III–IV Melanoma (RELATIVITY-098). Bristol-Myers Squibb.
Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611(7934):155–60. https://doi.org/10.1038/s41586-022-05368-8 .
doi: 10.1038/s41586-022-05368-8
Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–44.
doi: 10.1016/S0140-6736(20)30934-X
Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023;24(1):33–44.
doi: 10.1016/S1470-2045(22)00687-8
Chauvin J-M, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients. J Clin Investig. 2015;125(5):2046–58.
doi: 10.1172/JCI80445
Dummer R, Robert C, Scolyer RA, et al. Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro)+ vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma. Cancer Res. 2023;83(8_Supplement):CT002-CT002.
Arance A, De La Cruz-Merino L, Petrella TM, et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J Clin Oncol. 2023;41(1):75–85.
doi: 10.1200/JCO.22.00221
Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6.
doi: 10.1038/nature23003
Khattak A, Weber JS, Meniawy T, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. Am Soc Clin Oncol. 2023.